Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.55 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.50 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15676364 | 0.87 | CYP3A4 (0.77) | CYP3A4MEN1KMT2APTGS1DRD3 | |
| SCHEMBL1500125 | 0.86 | CYP3A4 (0.74) | CYP3A4MEN1KMT2APTGS1DRD3 | |
| SCHEMBL15372539 | 0.82 | CYP3A4 (0.69) | CYP3A4MEN1KMT2APTGS1DRD3 | |
| SCHEMBL2788789 | 0.82 | MEN1 (0.69) | CYP3A4MEN1KMT2APTGS1DRD3 | |
| SCHEMBL28312119 | 0.82 | MEN1 (0.69) | CYP3A4MEN1KMT2APTGS1DRD3 | |
| Hydrochloric Acid SCHEMBL28825358 | 0.80 | MEN1 (0.67) | CYP3A4MEN1KMT2APTGS1DRD3 | |
| SCHEMBL7550984 | 0.80 | CYP3A4 (0.67) | CYP3A4MEN1KMT2APTGS1DRD3 | |
| SCHEMBL7300081 | 0.79 | MEN1 (0.65) | CYP3A4MEN1KMT2APTGS1DRD3 | |
| SCHEMBL28155500 | 0.79 | CYP3A4 (0.65) | CYP3A4MEN1KMT2APTGS1DRD3 | |
| SCHEMBL2790900 | 0.79 | MEN1 (0.64) | CYP3A4MEN1KMT2APTGS1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 938 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250090501-A1 | METHODS OF TREATING GUT MOTILITY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-20 | — | — | US | claimed |
| US-20250009655-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC | 2025-01-09 | — | — | US | claimed |
| EP-4460293-A2 | METHODS OF TREATING GUT MOTILITY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-13 | — | — | EP | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | claimed |
| US-11794009-B2 | Devices, systems and methods for treating urological and gastrointestinal disorders by electrical stimulation of the foot | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-10-24 | — | — | US | claimed |
| WO-2023130149-A2 | METHODS OF TREATING GUT MOTILITY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | claimed |
| WO-2023064318-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC (US) | 2023-04-20 | — | — | WO | claimed |
| US-20060074108-A1 | Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition | BIODERM RESEARCH (US) | 2006-04-06 | — | — | US | claimed |
| CN-1730455-A | Phloroglucinol propionyl derivative and synthetic method thereof and application | BIOLOGY INST OF SHANDONG ACADE (CN) | 2006-02-08 | — | — | CN | claimed |
| US-20050271608-A1 | Skin whitening compositions based on hydroxyaryl alkyl ketones and their isosteric derivatives | GUPTA SHYAM K | 2005-12-08 | — | — | US | claimed |
| WO-2005035473-A2 | METHOD FOR PREPARING LADDERANES FROM PRE-ORIENTED POLYENES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2005-04-21 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | CYP3A4 4180/4885MEN1 4717/4885KMT2A 4648/4885 |
| US-20250090501-A1 | METHODS OF TREATING GUT MOTILITY DISORDERS | SI, SLC10A2, FABP2 | CYP3A4 1408/4885MEN1 3229/4885KMT2A 3191/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | CYP3A4 1995/4885MEN1 2593/4885KMT2A 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.